Lipocine Q3 revenue hits $2.29M as loss narrows
BLOOM is expected to enroll approximately 120 participants, while partner launches in Canada and the UAE are planned for early 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Lipocine Inc. reported third-quarter 2026 revenue of $2,290,072 for the quarter ended September 30, 2026, compared with $114,574 a year earlier, and a net loss of $666,192 versus $3,186,832. Diluted loss per share was $0.08, compared with $0.59. Unrestricted cash, cash equivalents and marketable investment securities were $21.5 million as of September 30, versus $14.9 million at December 31, 2025; the company reported approximately $28.5 million as of November 4, 2026, unaudited.
Lipocine announced the initiation of the BLOOM Phase 3 placebo-controlled outpatient study of LPCN 1154 for postpartum depression in September; it is expected to enroll approximately 120 participants. FDA feedback indicated the 505(b)(2) NDA package appeared complete except for a single positive and well-controlled Phase 3 trial. Health Canada approved TLANDO in September, and Verity Pharma plans a Canadian launch in early 2027. Pharmalink received UAE marketing authorization for TESTYRA in July and plans a launch there in early 2027.
Third-quarter revenue included $2.1 million of license and collaboration revenue and $190,000 in TLANDO royalties. Lipocine plans to submit a Phase 2 protocol for LPCN 2203 to the FDA; future studies are subject to resource prioritization.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue: $2,290,072, versus $114,574 in 2025.
- Moderate pointThird-quarter net loss fell to $666,192 from $3,186,832.
Negative
- None.
Filing Explained
Lipocine’s third-quarter balance sheet reports common shares outstanding rose from 6,158,443 at
8-K Event Classification
Key Figures
Key Terms
505(b)(2) pathway regulatory
New Drug Application (NDA) regulatory
placebo-controlled outpatient study medical
marketable investment securities financial
license and collaboration revenue financial
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did LPCN report in the third quarter of 2026?
What is Lipocine planning for LPCN 2201?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On November 5, 2026, the Company issued a press release announcing financial and operational results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibits are filed with this report:
| Exhibit No. | Description | |
| 99.1 | Press Release announcing Financial Results for the Quarter Ended September 30, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIPOCINE INC. | ||||
| Date: | November 5, 2026 | By: | /s/ Mahesh V. Patel | |
| Mahesh V. Patel | ||||
| President and Chief Executive Officer | ||||
Exhibit 99.1
Lipocine Announces Financial Results for the Third Quarter of 2026
SALT LAKE CITY, November 5, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update.
Recent Developments and Corporate Update
LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD)
In September 2026, Lipocine announced the initiation of the BLOOM (Brexanolone Lifting Outcomes of Moms) study. The Phase 3 placebo-controlled outpatient study is expected to enroll approximately 120 participants with PPD and is designed to generate prospective efficacy and safety evidence to support a potential New Drug Application (NDA) under the 505(b)(2) pathway. Feedback from a recent meeting with the FDA, including the necessity of a positive and well-controlled Phase 3 trial, together with learnings from the prior Phase 3 trial, are incorporated into the BLOOM study design. Further, feedback from the FDA acknowledged that the NDA submission package presented to FDA appears complete to support 505(b)(2) NDA submission with the exception of the need for a single positive and well controlled Phase 3 trial.
| ● | Lipocine continues to explore business partnerships for the development, approval and commercialization of BRLIZIO™ (LPCN 1154). |
Other Neuroactive Steroid Programs
| ● | LPCN 2201 for Major Depressive Disorder (MDD): Following planned clinical assessment of unique oral brexanolone formulations, Lipocine plans to submit a Phase 2 protocol to the FDA and may initiate a study of LPCN 2201 in MDD, subject to resource prioritization. | |
| ● | LPCN 2203 for Essential Tremor (ET): Lipocine has completed oral pharmacokinetic studies of LPCN 2203 and plans to submit a protocol for a proof-of-concept Phase 2 study in essential tremor to the FDA. Any future studies of LPCN 2203 will be subject to resource prioritization. |
TLANDO®
| ● | In September 2026, Health Canada approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Verity Pharma, Lipocine’s partner in North America, is planning for launch in Canada in early 2027. | |
| ● | In July 2026, Lipocine’s distribution partner Pharmalink received product marketing authorization approval in the United Arab Emirates for TESTYRA® (TLANDO). Pharmalink is planning for launch in the UAE in early 2027. | |
| ● | Lipocine continues to explore partnering TLANDO in territories outside the U.S., Canada, South Korea, the GCC countries and Brazil. |
Third Quarter Ended September 30, 2026 Financial Results
As of September 30, 2026, Lipocine had $21.5 million of unrestricted cash, cash equivalents and marketable investment securities, compared to $14.9 million at December 31, 2025. As of November 4, 2026, the Company had approximately $28.5 million of unrestricted cash, cash equivalents and marketable investment securities (unaudited).
Lipocine reported a net loss of $0.7 million, or ($0.08) per diluted share, for the quarter ended September 30, 2026, compared to a net loss of $3.2 million, or ($0.59) per diluted share, for the quarter ended September 30, 2025.
Lipocine recognized total revenue of $2.3 million during the quarter ended September 30, 2026, compared to $115,000 during the quarter ended September 30, 2025. Revenue for the third quarter of 2026 consisted of license and collaboration revenue of $2.1 million and royalty revenue from TLANDO sales of $190,000. Revenue for the third quarter of 2025 consisted entirely of royalty revenue from TLANDO sales.
Research and development expenses were $2.1 million and $2.7 million, respectively, for the quarters ended September 30, 2026 and 2025. The decrease primarily reflects lower costs related to the LPCN 2401 study, which was placed on hold in 2025, and lower LPCN 1154 clinical costs in 2026 compared with costs incurred for the prior Phase 3 study during the third quarter of 2025, partially offset by an increase in personnel costs.
General and administrative expenses were $1.1 million and $0.8 million, respectively, for the quarters ended September 30, 2026 and 2025. The increase primarily reflects higher personnel costs and higher legal fees related to protecting the Company’s intellectual property and promoting its corporate strategy.
Interest and investment income was $0.2 million for each of the quarters ended September 30, 2026 and 2025.
Nine Months Ended September 30, 2026 Financial Results
Lipocine reported a net loss of $7.0 million, or ($0.90) per diluted share, for the nine months ended September 30, 2026, compared to a net loss of $7.3 million, or ($1.35) per diluted share, for the nine months ended September 30, 2025.
Lipocine recognized revenue of $2.6 million and $831,000 during the nine months ended September 30, 2026 and 2025, respectively. Revenue for the 2026 period consisted of license and collaboration revenue of $2.1 million and royalty revenue from TLANDO sales of $500,000. Revenue for the 2025 period consisted of license revenue of $500,000 and royalty revenue from TLANDO sales of $331,000.
Research and development expenses were $6.9 million and $5.9 million, respectively, for the nine-month periods ended September 30, 2026 and 2025. The increase primarily reflects higher costs related to LPCN 1154 studies and other clinical trial costs, as well as an increase in personnel expense.
General and administrative expenses were $3.3 million and $2.8 million, respectively, for the nine-month periods ended September 30, 2026 and 2025. The increase primarily reflects higher legal fees related to protecting the Company’s intellectual property and promoting its corporate strategy, as well as an increase in personnel expense.
Interest and investment income was $0.6 million for each of the nine-month periods ended September 30, 2026 and 2025.
For further detail on Lipocine’s financial results for the three and nine months ended September 30, 2026, refer to the Company’s Form 10-Q filed with the SEC.
About Lipocine
Lipocine is a biopharmaceutical company developing oral therapeutics using its proprietary drug-delivery technology platform. The Company advances product candidates addressing significant unmet medical needs and explores partnerships to support their development and commercialization.
Lipocine’s development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
Forward Looking Statements
This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our development of our products and product candidates and related efforts with the FDA, including the design, planned enrollment, timing and potential outcomes of the BLOOM study; the sufficiency of existing financial and operational resources to execute the study; expected average monthly cash use, study expenditures and cash needs; the timing of clinical trials and regulatory submissions; the timing of anticipated commercial launches of licensed products; the potential uses and benefits of our products and product candidates; the commercial potential for our product candidates; and potential strategic partnerships and other opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of an NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, variability in enrollment and site performance, study costs exceeding current estimates, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
SOURCE Lipocine Inc.
For further information:
Krista Fogarty
Phone: (801) 994-7383
kf@lipocine.com
Investors:
PJ Kelleher
Phone: (617) 430-7579
pkelleher@lifesciadvisors.com
LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,594,151 | $ | 5,205,842 | ||||
| Marketable investment securities | 18,861,297 | 9,724,545 | ||||||
| Accrued interest income | 208,462 | 14,189 | ||||||
| License fee and royalties receivable | 690,071 | 1,145,390 | ||||||
| Prepaid and other current assets | 758,676 | 787,600 | ||||||
| Total current assets | 23,112,657 | 16,877,566 | ||||||
| Property and equipment, net of accumulated depreciation of $1,328,188 and $1,284,079 respectively | 60,184 | 104,293 | ||||||
| Other assets | 23,753 | 23,753 | ||||||
| Total assets | $ | 23,196,594 | $ | 17,005,612 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 544,347 | $ | 971,822 | ||||
| Accrued expenses | 1,170,099 | 1,236,374 | ||||||
| Deferred revenue | 320,000 | 320,000 | ||||||
| Total current liabilities | 2,034,446 | 2,528,196 | ||||||
| Total liabilities | 2,034,446 | 2,528,196 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, par value $0.0001 per share, 75,000,000 shares authorized; 8,245,798 and 6,158,779 issued and 8,245,462 and 6,158,443 outstanding, respectively | 9,153 | 8,944 | ||||||
| Additional paid-in capital | 237,577,314 | 223,901,106 | ||||||
| Treasury stock at cost, 336 shares | (40,712 | ) | (40,712 | ) | ||||
| Accumulated other comprehensive income | (26,559 | ) | 4,445 | |||||
| Accumulated deficit | (216,357,048 | ) | (209,396,367 | ) | ||||
| Total stockholders’ equity | 21,162,148 | 14,477,416 | ||||||
| Total liabilities and stockholders’ equity | $ | 23,196,594 | $ | 17,005,612 | ||||
LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
| Three
Months Ended September 30, | Nine
Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues: | ||||||||||||||||
| License revenue | $ | 2,100,000 | $ | - | $ | 2,100,000 | $ | 500,000 | ||||||||
| Royalty revenue | 190,072 | 114,574 | 499,568 | 331,287 | ||||||||||||
| Total revenues | 2,290,072 | 114,574 | 2,599,568 | 831,287 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 2,070,033 | 2,707,777 | 6,875,816 | 5,906,118 | ||||||||||||
| General and administrative | 1,088,564 | 767,837 | 3,283,987 | 2,780,747 | ||||||||||||
| Total operating expenses | 3,158,597 | 3,475,614 | 10,159,803 | 8,686,865 | ||||||||||||
| Operating loss | (868,525 | ) | (3,361,040 | ) | (7,560,235 | ) | (7,855,578 | ) | ||||||||
| Other income: | ||||||||||||||||
| Interest and investment income | 202,333 | 174,208 | 599,754 | 598,357 | ||||||||||||
| Total other income | 202,333 | 174,208 | 599,754 | 598,357 | ||||||||||||
| Loss before income tax expense | (666,192 | ) | (3,186,832 | ) | (6,960,481 | ) | (7,257,221 | ) | ||||||||
| Income tax expense | - | - | (200 | ) | (200 | ) | ||||||||||
| Net loss attributable to common shareholders Net loss attributable to common shareholders | $ | (666,192 | ) | $ | (3,186,832 | ) | $ | (6,960,681 | ) | $ | (7,257,421 | ) | ||||
| Basic loss per share attributable to common stock | $ | (0.08 | ) | $ | (0.59 | ) | $ | (0.90 | ) | $ | (1.35 | ) | ||||
| Weighted average common shares outstanding, basic | 8,244,542 | 5,413,149 | 7,757,487 | 5,371,458 | ||||||||||||
| Diluted loss per share attributable to common stock | $ | (0.08 | ) | $ | (0.59 | ) | $ | (0.90 | ) | $ | (1.35 | ) | ||||
| Weighted average common shares outstanding, diluted | 8,244,542 | 5,413,149 | 7,757,487 | 5,371,458 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (666,192 | ) | $ | (3,186,832 | ) | $ | (6,960,681 | ) | $ | (7,257,421 | ) | ||||
| Net unrealized gain (loss) on marketable investment securities | (13,158 | ) | 5,870 | (31,004 | ) | (4,511 | ) | |||||||||
| Comprehensive loss | $ | (679,350 | ) | $ | (3,180,962 | ) | $ | (6,991,685 | ) | $ | (7,261,932 | ) | ||||